

English Version

Chiesi at Glance 2022



A global company

Chiesi is an international biopharmaceutical group with strong local community roots. It is a **research-focused** company that develops and markets innovative therapeutic solutions in respiratory health, rare diseases and special care.

Chiesi's mission is to improve people's quality of life. For this reason, it acts responsibly towards patients, the environment, and the communities in which it operates, combining its commitment to results and integrity, both for society and the planet.






International biopharmaceutical Group, **B** Corp certified



Benefit Corporation in Italy (Società Benefit),





Turnover of **2 billion** and **749 million euros**





3 production plants (Italy, France and Brazil) and **31** affiliates Therapeutic solutions distributed in more than **100 countries**



Expertise areas: air. rare. care



7 R&D centers: Italy (Parma), Canada, China, France, United States, UK and Sweden. R&D investments: **21.4% of the revenues**



Committed to reach

Net Zero GHG emissions within 2035

Chiesi

Chiesi in the world

With its affiliates, Chiesi Group is present in various areas of the world and counts on a highly qualified entrepreneurial team characterised by **passion and collaborative spirit**.

Board of Directors

Alberto Chiesi

Paolo Chiesi Alessandro Chiesi Maria Paola Chiesi Giacomo Chiesi Andrea Chiesi Giuseppe Accogli

... and over time

1935

Chiesi is founded in Parma by Giacomo Chiesi, a chemist who dreams of doing research.

1960s

Giacomo Chiesi hands over management to his two sons Alberto and Paolo. They continue the international expansion of the company by opening its first affiliate in Brazil in the late 70s.

2000s

The third Chiesi generation joins the company and opens new R&D activities. The company keeps growing on an international level.

2020s

Chiesi announces its commitment to reach Net-Zero greenhouse gas (GHG) emissions by 2035. The Group launches the business unit Global Rare Diseases. The company obtains B Corp re-certification and starts focusing on biological medicines by investing in the new Biotech Center of Excellence. The acquisition of Amryt Pharma is completed.



です

People, the *heart* of the company



Research & Development: Chiesi's *strength*

The Group is strongly committed to R&D activities, both in terms of development (clinical research aiming to register **new drugs**) and in terms of applied research (identification of **new chemical and biological entities and different therapeutic solutions**), to which it dedicates a series of targeted projects. In 2022:

MEN

R&D People 1,102 > 687 of which researchers 35% 65%

WOMEN

Investments 21.4% Active projects **39**

EUROPEAN COMMISSION



1st among the Italian pharmaceutical companies* for R&D investments

Worldwide patents in the Chiesi

portfolio (until 12/31/2022)

2nd among the Italian manufacturing companies* **13th** among the European pharmaceutical companies*

With 42 new registered patents, in 2022, Chiesi was confirmed the **1**st Italian pharmaceutical company in Europe for patent deposits.

*European Commission - 2022 EU Industrial R&D Investment Scoreboard

The Biotech Center of Excellence

In 2022, Chiesi Group started working on the creation of a center of excellence for the development and production of biological drugs. The Biotech Center of Excellence will be based in Parma and will be operational from the first guarter of 2024. It will call on talent and technical competencies in order to develop know-how that covers all production steps, from cells to the finished drug to packaging for the global market.



Based in Parma



 \cap

105 People in highly-qualified positions

€85 million Investments in building and equipment





2021-2024





↔Chiesi

Shared Value & Sustainability

Chiesi believes that companies have the power and the means to make a difference. It is their responsibility to take care of the ecosystem in which they operate and its inhabitants. Business activities should extend beyond profit and consider the wider community acting as a force for good in the world.



Chiesi Impact Profile

When promoting sustainable progress and shared value in the healthcare sector, **actions mean more than words**. Chiesi commits to measuring its impact systematically both inside and outside the organisation. The Chiesi Impact Profile encompasses the following areas: **People, Governance, Patients, Environment, Value Chain, and Community**. The development of the profile originates from the impact areas mentioned above and covered in the B Impact Assessment (BIA)¹, the related scoring system and the company's Materiality Analysis².

The impact profile is endowed with a qualitative-quantitative description of actions in place and actions for improvement that Chiesi elects to use as a tool **to monitor its impact-related evolution and to define yearly and mid-term targets** and improvement plans across the organisation.

¹ The B Impact Assessment (BIA) is an internationally recognised measurement tool that allows companies to measure their impact on people, environment, society and territory.

² For further information please refer to the Sustainability Report 2022, available via QR Code on the last page of this document.

The governance model

Chiesi is a Benefit Corporation in Italy (Società Benefit), France (Société à Mission) and the United States. Therefore, it has incorporated into its statute **four common benefit goals**, to which in 2022 were added the company's long-term sustainability objectives:



Improving people's health, well-being and quality of life;



Innovating the sustainability of all company processes and practices continuously in order to minimise negative impacts and to amplify positive impacts on people, the biosphere and the community, in pursuit of an economy with Net-Zero GHG emissions, in line with European objectives on climate neutrality and national objectives on ecological transition;



Promoting a conscious and sustainable way of doing business by fostering a collaborative dialogue among stakeholders;



Contributing to the development of the local communities in which the company operates.



Chiesi is a B Corp certified company. This means **it takes full responsibility for its actions and its impact, committing to measure it day by day**.

It also means recognising of being part of an interdependent system, where longevity and prosperity depend on the health of the system itself.



In 2022, with a score of 103.8 out of 200 (+16.3 points compared to the first certification in 2019), Chiesi Group obtained the B Corp re-certification from B Lab.


Chiesi

Beyond the concept of *care*

Chiesi commits to **making a difference in the life** of patients, their families and their communities, developing sustainable therapeutic solutions and making them accessible for as many people as possible. Chiesi's commitment focuses on **3 main areas:**



Distribution of turnover by areas



2022 Achievements

Innovative treatments

Chiesi Group launched the acquisition of Amryt Pharma, an Irish biopharmaceutical company specialised in the treatment of rare diseases, which was formalised in January 2023.

A strategic partnership

Chiesi and Aptar Digital Health launched a collaboration to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD).

30 years in neonatology

In 2022, the company celebrated the 30th anniversary of its commitment to neonatology.

Digital Health

In 2022, "Kaia COPD", an app for the pulmonary rehabilitation of COPD patients, developed by Kaia Health, one of Chiesi's commercial partners, was included in the German DiGA directory. Doctors and psychotherapists can now prescribe it, since it can be refunded by compulsory health insurance and private health insurance.

From words to actions: Net Zero

ACTION OVER WORDS

Chiesi promotes a concept of sustainability that focuses on facts instead of words. The aim is **to stimulate a positive dialogue** on the concrete role that companies can play in the fight against climate change and on the need to switch from the celebration of commitments to real actions and measurable progress. In this sense, the Group is committed to achieving Net Zero Greenhouse Gas Emissions (GHG) of Scope 1 and Scope 2 by 2030, and of Scope 3 by 2035.

CHIESI ADHERES TO





U.S. Health Care Sector Climate Pledge

In 2022, Chiesi Group joined the Biden Administration by signing, together with other healthcare sector realities, the Health Care Sector Climate Pledge promoted by the Department of Health and Human Services (HHS). The aim is **to take meaningful actions in order to reduce the healthcare sector's climate footprint** and to make the system more resilient to climate change effects.

Carbon Minmal Inhaler

In 2019, Chiesi announced a **€350 million investment** to develop a low global warming potential spray inhaler (pressurised metered dose inhaler - pMDI) for the correct release of asthma and chronic obstructive pulmonary disease (COPD) drugs.

The project, which is expected to last seven years, will allow Chiesi **to reduce by 90% its Scope 3 GHG emissions** related to the use of sold products by 2035.

11

2022 Achievements

SCOPE 1

The production plants in Parma (Italy) and Blois (France) are equipped with a GHG emissions abatement system that prevents the dispersion of propellants, resulting from the production process of spray inhalers, into the atmosphere.



-16.7% compared to 2021

SCOPE 2



SCOPE 3

99% of electric consumption of all Chiesi sites comes from renewable sources.

> The percentage of renewable electricity increased

2019	20%	
2021		93%
2022		99%



The recycling process involved more than:

76% of produced waste in 2022

up from about **62%** in 2021



Chiesi has started a collaboration with its own value chain that allows to map all the produced emissions, with the aim of reducing the climate impact of the whole supply chain.

Value Chain Sustainability

In 2019, Chiesi co-created, alongside its business partners, the **Code of Interdependence**, the code of conduct for suppliers, which has been rolled out globally.

The Code of Interdependence **changes the concept of a value chain** into an ecosystem, which recognises each actor as essential to the others, within a process of mutual learning and co-evolution. The Code includes both **mandatory requirements** which represent a minimum level to be implemented, and **improvement actions** which represent a guide for those that wish to go even further towards implementing future improvements of the principles outlined in the document.





of Chiesi expenditure was covered by vendor qualification process.



of Chiesi strategic expenditure is certified by the EcoVadis platform.



were covered by the Code of Interdependece

C+Chiesi

Alongside the *local communities*

"Contributing to the development of the local communities in which the company operates" is one of the common benefit goals that Chiesi has included in its legal status. The Committee for Social Development Activities in the Community (CASSC) is committed to defining the strategy that the Group wants to follow to promote the development of the Parma community.

Activities are implemented both at Headquarters level and in the affiliates. Country representatives take care of local activities to ensure that in the whole Group activities are chosen based on the main areas of action:



Environment protection









Social innovation and inclusion



Emergency



Culture and attractiveness of the area



9,000

ቍ

26M

Donations and other social contributions as identified

by the Business for Societal Impact Guidance Manual

130,000 units of donated drugs

£4.5M total value of donated drugs


(such as sponsorships, external studies and clinical trials)

Group employees engaged in voluntary activites

at group level

hours of volunteering

Economic value generated and distributed



Capital providers

Community

Sustainability Report

As a Benefit Corporation and B Corp certified company, Chiesi Farmaceutici carefully assesses its economic, social and governance sustainability performance every year.

Measuring and evaluating each operation is a fundamental aspect of the company commitment to **transparency and accountability** towards the community. Progress in the crucial areas of work is regularly assessed, clearly identifying areas for improvement.



Frame the QR code to read the Sustainability Report 2022 The Sustainability Report provides a complete and precise summary of how Chiesi promotes **sustainable care**, together with patients, partners, suppliers and healthcare professionals who are an integral part of its system.





Chiesi Farmaceutici S.p.A. Via Palermo, 26/A - 43122 Parma - Italy Tel. +39 0521 2791

chiesi.com

Certified This company meets high standards of social and environmental impact.